An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Positive Phase 3 Trial Results for Lilly’s Oral Weight-Loss Drug, Orforglipron On August 7, Eli Lilly and Company announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in 3,127 adults...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves SKYTROFA® for the Once-Weekly Treatment of Adults with GHD On July 28, Ascendis Pharma A/S announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA® (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Recordati Rare Diseases Announced New Data in Cushing’s Syndrome, Cushing’s Disease, and Post-Bariatric Hypoglycaemia at ENDO 2025 In April 2025, the FDA approved an expanded indication for ISTURISA® (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome Recordati Rare...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Results from AMGEN’S Phase 2 Obesity Study OF Monthly MariTide Presented at The American Diabetes Association 85th Scientific Sessions MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau,...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * MiniMed to be Metronic’s New Diabetes Company On June 12, Medtronic plc announced MiniMed as the name for the planned New Diabetes Company following the intended separation. The name honors the company’s roots, reflecting its original name prior to its acquisition by...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist On June 2, Regeneron Pharmaceuticals, Inc., announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of the...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome On May 12, Amylyx Pharmaceuticals, Inc. announced positive Week 48 data from the Phase 2 open-label HELIOS clinical trial of AMX0035 (sodium phenylbutyrate [PB] and...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * New OTC Weight Loss Pill Granted Patent On May 6, Olfactive Biosolutions was granted a patent for formulations of food molecules that cause significant weight loss when taken as a daily pill. The company’s Pivit supplement induces the simultaneous secretion of...
